Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Clinical trial NCT04774380 · COMPLETED
Trial details
- NCT number
- NCT04774380
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-11
- Primary completion
- 2023-06-12
- Enrollment
- 152
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.